Apixaban for the prevention of venous thromboembolism in people ...

5 COST EFFECTIVENESS ....................................................................................................... 33
5.1 ERG comment on manufacturer’s review of cost-effectiveness evidence ............................ 33
5.1.1 State objective of cost effectiveness review. Provide description of manufacturers
search strategy and comment on whether the search strategy was appropriate. If the
manufacturer did not perform a systematic review, was this appropriate? ................................ 33
5.1.2 State the inclusion/exclusion criteria used in the study selection and comment on
whether they were appropriate. ................................................................................................ 33
5.1.3 What studies were included in the cost effectiveness review and what were excluded?
Where appropriate, provide a table of identified studies. Please identify the most important cost
effectiveness studies. ............................................................................................................... 33
5.1.4 What does the review conclude from the data available? Does the ERG agree with the
conclusions of the cost effectiveness review? If not, provide details......................................... 34
5.2 Summary and critique of manufacturer’s submitted economic evaluation by the ERG ....... 36
5.2.1 NICE reference case checklist (TABLE ONLY) ....................................................... 36
5.2.2 Model structure ........................................................................................................ 37
5.2.3 Population ................................................................................................................ 40
5.2.4 Interventions and comparators .................................................................................. 40
5.2.5 Perspective, time horizon and discounting ................................................................ 41
5.2.6 Treatment effectiveness ............................................................................................ 42
5.2.7 Health related quality of life ..................................................................................... 47
5.2.8 Resources and costs .................................................................................................. 49
5.2.9 Cost effectiveness results .......................................................................................... 53
5.2.10 Sensitivity analyses .................................................................................................. 57
5.2.11 Model validation ...................................................................................................... 66
5.3 Additional work undertaken by the ERG ........................................................................... 66
5.4 Conclusions ..................................................................................................................... 69
6 Impact on the ICER of additional clinical and economic analyses undertaken by the ERG ....... 69
7 End of life ............................................................................................................................... 69
8 Conclusions ............................................................................................................................ 69
8.1 Implications for research ................................................................................................. 70
References....................................................................................................................................... 71
Appendix 1A: ERG Search Strategies .............................................................................................. 77
Appendix 1B: Review of search strategies for Apixaban studies ...................................................... 87
Appendix 2: Phillips et al. Checklist ................................................................................................ 89
6
Copyright 2011 Queen’s Printer and Controller of HMSO. All rights reserved.